FY2024 EPS Estimates for TSE:BHC Lifted by Zacks Research

Bausch Health Companies Inc. (TSE:BHC) – Zacks Research increased their FY2024 earnings per share estimates for Bausch Health Companies in a research report issued to clients and investors on Wednesday, November 20th. Zacks Research analyst R. Department now anticipates that the company will post earnings of $5.21 per share for the year, up from their previous estimate of $4.98. The consensus estimate for Bausch Health Companies’ current full-year earnings is $5.55 per share. Zacks Research also issued estimates for Bausch Health Companies’ Q4 2024 earnings at $1.57 EPS, Q1 2025 earnings at $1.19 EPS, Q2 2025 earnings at $1.40 EPS, Q3 2025 earnings at $1.57 EPS, Q4 2025 earnings at $1.79 EPS, FY2025 earnings at $5.96 EPS, Q1 2026 earnings at $1.51 EPS, Q2 2026 earnings at $1.57 EPS, Q3 2026 earnings at $1.90 EPS and FY2026 earnings at $7.01 EPS.

Separately, Evercore ISI raised shares of Bausch Health Companies to a “hold” rating in a report on Tuesday, October 15th.

Bausch Health Companies Stock Down 0.3 %

BHC opened at C$11.45 on Friday. Bausch Health Companies has a twelve month low of C$5.45 and a twelve month high of C$15.43. The company’s 50-day moving average price is C$11.22 and its two-hundred day moving average price is C$9.86. The stock has a market cap of C$4.20 billion, a price-to-earnings ratio of -6.54, a PEG ratio of 0.21 and a beta of 0.77. The company has a quick ratio of 0.58, a current ratio of 1.19 and a debt-to-equity ratio of 7,583.76.

Bausch Health Companies (TSE:BHC) last issued its quarterly earnings results on Wednesday, October 30th. The company reported C$1.53 earnings per share for the quarter, topping analysts’ consensus estimates of C$1.43 by C$0.10. Bausch Health Companies had a negative net margin of 5.12% and a negative return on equity of 2,304.54%. The company had revenue of C$3.42 billion for the quarter, compared to the consensus estimate of C$3.36 billion.

Insider Transactions at Bausch Health Companies

In other news, Senior Officer Seana Lynne Carson sold 13,370 shares of the business’s stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of C$8.38, for a total value of C$112,087.40. 11.28% of the stock is owned by corporate insiders.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.